GlassScriptPhysician profile
James T Henry
NPI 1912995713
$5,493.18
in general payments reported to CMS, 2019-2025
32 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $81.98 · 2021: $222 · 2022: $588 · 2023: $1,053 · 2024: $1,067 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726 · Travel and Lodging: $1,515 · Education: $49.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,725.80 |
| Travel and Lodging | $1,515.11 |
| Education | $49.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $1,990.43 | 2025 | Renal - Chronic, Renal - Pd |
| Amgen INC. | $469.48 | 2021-2025 | Tavneos, Parsabiv, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $362.67 | 2019-2024 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $278.16 | 2019-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $251.14 | 2022-2025 | Optiflux, Crit-Line, 2008t Bluestar Hemodialysis Machine |
| Horizon Therapeutics Plc | $223.24 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $195.07 | 2022-2024 | |
| Vifor Pharma, INC. | $187.78 | 2019-2023 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $178.76 | 2021-2024 | Benlysta |
| Novo Nordisk INC | $174.70 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Aurinia Pharma U.S., INC. | $161.20 | 2022-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $144.17 | 2019-2024 | Jynarque |
| Travere Therapeutics, INC. | $128.95 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $107.41 | 2023-2025 | |
| Ardelyx, INC. | $92.46 | 2023-2024 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $73.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.36 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $51.12 | 2024 | Xarelto |
| Calliditas Therapeutics US INC. | $50.06 | 2023-2024 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $46.42 | 2023 | |
| Ani Pharmaceuticals, INC. | $41.90 | 2022-2023 | Purified Cortrophin Gel |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.56 | 2025 | Caplyta |
| Organon LLC | $26.70 | 2024 | |
| Abbvie INC. | $21.63 | 2021 | |
| Bard Peripheral Vascular, INC. | $20.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.14 | 2023 | Gattex |
| Xeris Pharmaceuticals, INC. | $19.43 | 2024 | Keveyis |
| Kyowa Kirin, INC. | $19.08 | 2023 | Crysvita |
| Daiichi Sankyo INC. | $18.16 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.08 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.77 | 2019 | |
| Pharmacosmos Therapeutics INC. | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.